Aquestive Therapeutics, Inc.
AQST Nasdaq
SEC CIK 1398733
Follow Aquestive Therapeutics
Weekly email: filings, results
Revenue, last quarter
$7.6M
−41% vs same quarter last year
Net income
−$16.5M
−6.8% vs same quarter last year
EPS, diluted
−$0.13
+7.1% vs same quarter last year
Operating cash flow
−$7M
+44.3% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $44.5M | −$83.8M |
| FY24 | $57.6M | −$44.1M |
| FY23 | $50.6M | −$7.9M |
| FY22 | $47.7M | −$54.4M |
| FY21 | $50.8M | −$70.5M |
| FY20 | $45.8M | −$55.8M |
| FY19 | $52.6M | −$66.2M |
| FY18 | $67.4M | −$61.4M |
| FY17 | $66.9M | −$8.9M |
| FY16 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 58.3% | −159.5% | −188.1% |
| FY24 | 69% | −53.5% | −76.7% |
| FY23 | 58.8% | −29.9% | −15.6% |
| FY22 | 59.3% | −88.2% | −114.1% |
| FY21 | - | −68.2% | −138.8% |
| FY20 | 71.7% | −93.6% | −121.7% |
| FY19 | 61.3% | −100.1% | −125.9% |
| FY18 | - | −72.6% | −91% |
| FY17 | - | −0.2% | −13.4% |
| FY16 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$53M |
| FY24 | −$35.9M |
| FY23 | −$7.4M |
| FY22 | −$10.8M |
| FY21 | −$33.9M |
| FY20 | −$46M |
| FY19 | −$60.9M |
| FY18 | −$14.8M |
| FY17 | $3.8M |
| FY16 | - |
- Aquestive Therapeutics
- Healthcare median
Show the numbers
| Year | Aquestive Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −188.1% | −30.6% |
| FY24 | −76.7% | −47% |
| FY23 | −15.6% | −58% |
| FY22 | −114.1% | −80.4% |
| FY21 | −138.8% | −71.8% |
| FY20 | −121.7% | −62.2% |
| FY19 | −125.9% | −46.2% |
| FY18 | −91% | −49.6% |
| FY17 | −13.4% | −45.9% |
| FY16 | - | −36% |